fidaxomicin
ApprovedCompleted 0 watching 0 views this week🔥 Hot
85
Development Stage
✓
Pre-clinical✓
Phase 1✓
Phase 2✓
Phase 35
ApprovedIndication / Disease
Inflammatory Bowel Disease (IBD)
Conditions
Inflammatory Bowel Disease (IBD), Clostridium Difficile Infection (CDI)
Trial Timeline
Aug 13, 2015 → Oct 24, 2016
NCT ID
NCT02437591About fidaxomicin
fidaxomicin is a approved stage product being developed by Astellas Pharma for Inflammatory Bowel Disease (IBD). The current trial status is completed. This product is registered under clinical trial identifier NCT02437591. Target conditions include Inflammatory Bowel Disease (IBD), Clostridium Difficile Infection (CDI).
Hype Score Breakdown
Clinical
30
Activity
20
Company
10
Novelty
10
Community
12
Clinical Trials (1)
| NCT ID | Phase | Status |
|---|---|---|
| NCT02437591 | Approved | Completed |
Competing Products
20 competing products in Inflammatory Bowel Disease (IBD)
| Product | Company | Stage | Hype Score |
|---|---|---|---|
| Infliximab + Infliximab + Infliximab | Celltrion | Approved | 85 |
| CT-P13 | Celltrion | Phase 3 | 77 |
| Subcutaneous infliximab CT-P13 Remsima®SC | Celltrion | Pre-clinical | 23 |
| Infliximab subcutaneous + Immunosuppressive Agents | Celltrion | Phase 3 | 77 |
| Eribulin + Adriamycin + Cyclophosphamide | Eisai | Phase 2 | 52 |
| E6007 + E6007 + E6007 + E6007 + E6007 + E6007 | Eisai | Phase 1 | 33 |
| Placebo + MORF-057 | Eli Lilly | Phase 2 | 52 |
| Baricitinib + Baricitinib | Eli Lilly | Phase 2 | 52 |
| LY3114062 SC + Placebo + LY3114062 IV | Eli Lilly | Phase 1 | 33 |
| MORF-057 + Placebo | Eli Lilly | Phase 2 | 52 |
| MORF-057 | Eli Lilly | Phase 2 | 52 |
| LY3009104 | Eli Lilly | Phase 1 | 33 |
| HRF2105 patch + Loxoprofen patch + placebo | Jiangsu Hengrui Medicine | Phase 2 | 52 |
| Risankizumab | AbbVie | Approved | 85 |
| GC012F Injection infusion | AstraZeneca | Phase 1 | 33 |
| AZD6793 + Placebo | AstraZeneca | Phase 1 | 33 |
| Human Papillomavirus Vaccine | Merck | Approved | 85 |
| Pembrolizumab | Merck | Phase 2 | 52 |
| Gardasil vaccine | Merck | Pre-clinical | 23 |
| Bezlotoxumab | Merck | Approved | 85 |